SCHEMBL10299109

SCHEMBL10299109

Cc1cccc(CCC(=O)Nc2ncc(Cc3ccc(C(F)(F)F)cc3)s2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.59
▸ NPC1 O15118 5/20 0.59
▸ RAB9A P51151 5/20 0.59
▸ KMT2A Q03164 5/20 0.59
▸ MAPT P10636 4/20 0.59
▸ KDM4E B2RXH2 4/20 0.59
▸ ALDH1A1 P00352 2/20 0.59
▸ HPGD P15428 2/20 0.59
▸ ABL1 P00519 3/20 0.56
▸ SIRT2 Q8IXJ6 3/20 0.55
▸ SCD O00767 5/20 0.53
▸ LMNA P02545 4/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ TP53 P04637 1/20 0.50
▸ NFKB1 P19838 3/20 0.49
▸ NFKB2 Q00653 3/20 0.49
▸ RELA Q04206 3/20 0.49
▸ GAA P10253 1/20 0.49
▸ CYP1A2 P05177 1/20 0.48
▸ POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10009298 0.88 LMNA (0.55) MEN1NPC1RAB9AKMT2AMAPT
SCHEMBL10009103 0.88 SCD (0.64) MEN1KMT2AMAPTABL1SCD
SCHEMBL10299099 0.85 KMT2A (0.63) MEN1NPC1RAB9AKMT2AMAPT
SCHEMBL10009261 0.84 ABL1 (0.50) MEN1NPC1RAB9AKMT2AMAPT
SCHEMBL10008763 0.84 MEN1 (0.57) MEN1NPC1RAB9AKMT2AMAPT
SCHEMBL10299104 0.83 MAPT (0.63) MEN1NPC1RAB9AKMT2AMAPT
SCHEMBL10299103 0.83 KMT2A (0.57) MEN1NPC1RAB9AKMT2AMAPT
SCHEMBL16085538 0.82 LMNA (0.53) MEN1NPC1RAB9AKMT2AMAPT
SCHEMBL10299101 0.81 KMT2A (0.60) MEN1NPC1RAB9AKMT2AMAPT
SCHEMBL16085406 0.79 NPC1 (0.54) MEN1NPC1RAB9AKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883793-B2 Tubulin inhibitors and methods of using the same DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2014-11-11 — — US disclosed
US-20120172374-A1 NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2012-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172374-A1 NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME TUBB1, TUBA1C, TUBB MEN1 740/4885NPC1 1216/4885RAB9A 1099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback